Investigation into Aquestive Therapeutics' Risk Disclosures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy AQST?
Source: Globenewswire
- Stock Price Plunge: On January 9, 2026, Aquestive's shares plummeted from $6.21 to $3.91, resulting in a single-day loss of $2.30 per share, over 37%, reflecting investor concerns over FDA regulatory deficiencies.
- Inadequate Risk Disclosures: Between June 16, 2025, and January 8, 2026, Aquestive's SEC filings utilized standard risk factor language without specifying known issues affecting the Anaphylm NDA, leaving investors unaware of the actual risk profile.
- Legal Challenge: A lawsuit has been filed by investors questioning the company's failure to disclose specific regulatory hurdles, arguing that generic risk warnings cannot substitute for specific known issues, thereby undermining investor rights.
- Investor Rights Protection: Levi & Korsinsky LLP is evaluating the eligibility of affected investors for claims, with a deadline of May 4, 2026, highlighting the importance of legal support for investor rights and recovery of losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AQST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.230
Low
6.00
Averages
9.00
High
12.00
Current: 4.230
Low
6.00
Averages
9.00
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Reminds of Aquestive Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to represent other class members in the lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket fees or costs, as all expenses will be handled through a contingency fee arrangement, which reduces financial risk for investors and encourages broader participation.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its expertise and success in handling such cases, which investors should consider when selecting legal counsel.
- Case Details: The lawsuit alleges that Aquestive concealed the true state of its New Drug Application, leading to investor losses when the market became aware of the facts, highlighting the importance of transparency and disclosure in securities investment.
See More
Reminder of Class Action for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiffs by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors and encouraging more affected parties to participate.
- Case Background: The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application, failing to disclose critical human factors in the use of its sublingual film, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, emphasizing the importance of selecting experienced legal counsel to ensure effective protection of investor rights.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Aquestive Therapeutics in the U.S. District Court for New Jersey on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, alleging misleading statements regarding the New Drug Application process.
- FDA Deficiency Disclosure: The complaint states that on January 9, 2026, Aquestive revealed it received a letter from the FDA identifying deficiencies in its NDA for Anaphylm, which delayed the product's launch and indicated the company failed to secure approval by the PDUFA date.
- Stock Price Plunge: Following this announcement, Aquestive's stock price plummeted over 37%, from $6.21 per share on January 8, 2026, to $3.91 per share, reflecting significant market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to protect their legal rights, indicating that the outcome of this lawsuit could have profound implications for the company's operations and shareholder confidence.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by May 4, 2026, to protect their rights.
- FDA Regulatory Issues: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, which has indefinitely delayed the approval process, negatively impacting the company's market outlook.
- Significant Stock Decline: Following the FDA notification, Aquestive's stock price plummeted by $2.30, a 37.04% drop, closing at $3.91, reflecting market pessimism regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, with a long history of recovering multimillion-dollar damages for victims, demonstrating its strong capabilities in the legal field.
See More
Faruqi & Faruqi Investigates Securities Fraud Claims Against Aquestive
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc., particularly for investors who purchased securities between June 16, 2025, and January 8, 2026, indicating possible securities fraud.
- Stock Price Plunge: On January 9, 2026, the stock price fell by $2.30, or 37.04%, closing at $3.91, following FDA notification of deficiencies in the NDA for Anaphylm, reflecting market concerns over the company's compliance and future prospects.
- Class Action Reminder: The firm reminds investors that May 4, 2026, is the deadline to seek lead plaintiff status in the federal securities class action, emphasizing the importance of investor participation and potential economic benefits in the legal process.
- Information Solicitation: Faruqi & Faruqi encourages anyone with knowledge of Aquestive's conduct, including whistleblowers and former employees, to come forward, demonstrating the firm's commitment to thorough investigation and protection of investor rights.
See More
Class Action Lawsuit Filed Against Aquestive
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Aquestive Therapeutics in New Jersey on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, raising concerns about the company's compliance and transparency.
- Allegation Details: The complaint alleges that during the class period, Aquestive misled investors by claiming its New Drug Application (NDA) would be approved by January 31, 2026, while the FDA identified deficiencies that delayed the approval of Anaphylm, undermining investor confidence.
- Stock Price Impact: Following the announcement on January 9, 2026, that the FDA had identified deficiencies, Aquestive's stock price plummeted over 37% from $6.21 on January 8 to $3.91, reflecting a pessimistic outlook from the market regarding the company's future.
- Next Steps: Investors must apply by May 4, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to assist affected investors in understanding their legal rights and potential compensation options.
See More
Rosen Law Firm Reminds of Aquestive Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to represent other class members in the lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket fees or costs, as all expenses will be handled through a contingency fee arrangement, which reduces financial risk for investors and encourages broader participation.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its expertise and success in handling such cases, which investors should consider when selecting legal counsel.
- Case Details: The lawsuit alleges that Aquestive concealed the true state of its New Drug Application, leading to investor losses when the market became aware of the facts, highlighting the importance of transparency and disclosure in securities investment.
See More
Reminder of Class Action for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiffs by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors and encouraging more affected parties to participate.
- Case Background: The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application, failing to disclose critical human factors in the use of its sublingual film, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, emphasizing the importance of selecting experienced legal counsel to ensure effective protection of investor rights.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Aquestive Therapeutics in the U.S. District Court for New Jersey on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, alleging misleading statements regarding the New Drug Application process.
- FDA Deficiency Disclosure: The complaint states that on January 9, 2026, Aquestive revealed it received a letter from the FDA identifying deficiencies in its NDA for Anaphylm, which delayed the product's launch and indicated the company failed to secure approval by the PDUFA date.
- Stock Price Plunge: Following this announcement, Aquestive's stock price plummeted over 37%, from $6.21 per share on January 8, 2026, to $3.91 per share, reflecting significant market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to protect their legal rights, indicating that the outcome of this lawsuit could have profound implications for the company's operations and shareholder confidence.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by May 4, 2026, to protect their rights.
- FDA Regulatory Issues: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, which has indefinitely delayed the approval process, negatively impacting the company's market outlook.
- Significant Stock Decline: Following the FDA notification, Aquestive's stock price plummeted by $2.30, a 37.04% drop, closing at $3.91, reflecting market pessimism regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation in securities and antitrust, with a long history of recovering multimillion-dollar damages for victims, demonstrating its strong capabilities in the legal field.
See More
Faruqi & Faruqi Investigates Securities Fraud Claims Against Aquestive
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc., particularly for investors who purchased securities between June 16, 2025, and January 8, 2026, indicating possible securities fraud.
- Stock Price Plunge: On January 9, 2026, the stock price fell by $2.30, or 37.04%, closing at $3.91, following FDA notification of deficiencies in the NDA for Anaphylm, reflecting market concerns over the company's compliance and future prospects.
- Class Action Reminder: The firm reminds investors that May 4, 2026, is the deadline to seek lead plaintiff status in the federal securities class action, emphasizing the importance of investor participation and potential economic benefits in the legal process.
- Information Solicitation: Faruqi & Faruqi encourages anyone with knowledge of Aquestive's conduct, including whistleblowers and former employees, to come forward, demonstrating the firm's commitment to thorough investigation and protection of investor rights.
See More
Class Action Lawsuit Filed Against Aquestive
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Aquestive Therapeutics in New Jersey on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, raising concerns about the company's compliance and transparency.
- Allegation Details: The complaint alleges that during the class period, Aquestive misled investors by claiming its New Drug Application (NDA) would be approved by January 31, 2026, while the FDA identified deficiencies that delayed the approval of Anaphylm, undermining investor confidence.
- Stock Price Impact: Following the announcement on January 9, 2026, that the FDA had identified deficiencies, Aquestive's stock price plummeted over 37% from $6.21 on January 8 to $3.91, reflecting a pessimistic outlook from the market regarding the company's future.
- Next Steps: Investors must apply by May 4, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to assist affected investors in understanding their legal rights and potential compensation options.
See More
